In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.
Published: December 02, 2020
Category: Group updates
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth).
This is a volunteer role for membership on the Head & Neck General Committee, the Head & Neck Executive Committee, and the CCTG Patient Representative Committee. Patient Representatives participate in all aspects of their Site Committee activities, and collectively all Site Committee Patient Representatives make up the CCTG Patient Representative Committee.
CCTG would like to extend congratulations to Dr. Kelvin Chan the recipient of the 2020 Dr. Maurice McGregor Award from Canadian Agency for Drugs and Technologies in Health (CADTH). The Dr. Maurice McGregor Award, honours rising stars early in their careers.
The Canadian Cancer Society Awards for Excellence in Cancer Research recognize individuals who have made, and are making, valuable contributions to the cancer research ecosystem in Canada. Recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community. There are two new awards this year find out more here.
Lead author Dr. Arjun Sahgal, deputy chief of radiation oncology at the Sunnybrook Health Sciences Centre of the University of Toronto, presented the findings from the CCTG SC24 at the American Society for Radiation Oncology (ASTRO) Annual Meeting last week. This randomized phase II/III trial is the first to show that stereotactic body radiation therapy is superior to conventional radiation treatments in alleviating pain from spinal metastases.